Literature DB >> 30069390

How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team.

Yalei Zhang1, Jianfei Shen2, Charles B Simone3, Federico Cappuzzo4, Kwun M Fong5, Rafael Rosell6, Joe Y Chang7, Luca Ampollini8, J Isabelle Choi3, Jianxing He1, Tao Jiang9.   

Abstract

Entities:  

Year:  2018        PMID: 30069390      PMCID: PMC6051847          DOI: 10.21037/jtd.2018.06.101

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  20 in total

1.  Additional data in the debate on stage I non-small cell lung cancer: surgery versus stereotactic ablative radiotherapy.

Authors:  Charles B Simone; Jay F Dorsey
Journal:  Ann Transl Med       Date:  2015-08

2.  Lung cancer's real adjuvant EGFR targeted therapy questions.

Authors:  Terry L Ng; D Ross Camidge
Journal:  Lancet Oncol       Date:  2017-11-21       Impact factor: 41.316

3.  Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline.

Authors:  Gregory M M Videtic; Jessica Donington; Meredith Giuliani; John Heinzerling; Tomer Z Karas; Chris R Kelsey; Brian E Lally; Karen Latzka; Simon S Lo; Drew Moghanaki; Benjamin Movsas; Andreas Rimner; Michael Roach; George Rodrigues; Shervin M Shirvani; Charles B Simone; Robert Timmerman; Megan E Daly
Journal:  Pract Radiat Oncol       Date:  2017-06-05

4.  Stereotactic body radiation therapy versus surgical resection for stage I non-small cell lung cancer.

Authors:  Traves D Crabtree; Chadrick E Denlinger; Bryan F Meyers; Issam El Naqa; Jennifer Zoole; A Sasha Krupnick; Daniel Kreisel; G Alexander Patterson; Jeffrey D Bradley
Journal:  J Thorac Cardiovasc Surg       Date:  2010-04-18       Impact factor: 5.209

5.  Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.

Authors:  Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth
Journal:  Lancet Oncol       Date:  2015-05-13       Impact factor: 41.316

Review 6.  Risk factors and management of oligometastatic non-small cell lung cancer.

Authors:  Akshar N Patel; Charles B Simone; Salma K Jabbour
Journal:  Ther Adv Respir Dis       Date:  2016-04-08       Impact factor: 4.031

7.  Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer.

Authors:  Inga S Grills; Victor S Mangona; Robert Welsh; Gary Chmielewski; Erika McInerney; Shannon Martin; Jennifer Wloch; Hong Ye; Larry L Kestin
Journal:  J Clin Oncol       Date:  2010-01-11       Impact factor: 44.544

8.  Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.

Authors:  Wen-Zhao Zhong; Qun Wang; Wei-Min Mao; Song-Tao Xu; Lin Wu; Yi Shen; Yong-Yu Liu; Chun Chen; Ying Cheng; Lin Xu; Jun Wang; Ke Fei; Xiao-Fei Li; Jian Li; Cheng Huang; Zhi-Dong Liu; Shun Xu; Ke-Neng Chen; Shi-Dong Xu; Lun-Xu Liu; Ping Yu; Bu-Hai Wang; Hai-Tao Ma; Hong-Hong Yan; Xue-Ning Yang; Qing Zhou; Yi-Long Wu
Journal:  Lancet Oncol       Date:  2017-11-21       Impact factor: 41.316

9.  Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Authors:  Daniel R Gomez; George R Blumenschein; J Jack Lee; Mike Hernandez; Rong Ye; D Ross Camidge; Robert C Doebele; Ferdinandos Skoulidis; Laurie E Gaspar; Don L Gibbons; Jose A Karam; Brian D Kavanagh; Chad Tang; Ritsuko Komaki; Alexander V Louie; David A Palma; Anne S Tsao; Boris Sepesi; William N William; Jianjun Zhang; Qiuling Shi; Xin Shelley Wang; Stephen G Swisher; John V Heymach
Journal:  Lancet Oncol       Date:  2016-10-24       Impact factor: 41.316

10.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

View more
  2 in total

1.  Management of stage IA EGFR-mutant adenocarcinoma of the lung.

Authors:  Robert Pirker
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

Review 2.  Implementation of lung cancer multidisciplinary teams: a review of evidence-practice gaps.

Authors:  Nicole M Rankin; Elizabeth A Fradgley; David J Barnes
Journal:  Transl Lung Cancer Res       Date:  2020-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.